| 000 | 01747 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514002605.0 | ||
| 264 | 0 | _c20010712 | |
| 008 | 200107s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 024 | 7 |
_a10.1038/sj.leu.2402137 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNakajima, A | |
| 245 | 0 | 0 |
_aABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. _h[electronic resource] |
| 260 |
_bLeukemia _cJun 2001 |
||
| 300 |
_a989-90 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 |
_aBlast Crisis _xpathology |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xpathology |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOncogene Proteins v-abl _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xpathology |
| 650 | 0 | 4 |
_aProtein Processing, Post-Translational _xdrug effects |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 | _aSubstrate Specificity |
| 650 | 0 | 4 |
_aTumor Cells, Cultured _xdrug effects |
| 700 | 1 | _aTauchi, T | |
| 700 | 1 | _aOhyashiki, K | |
| 773 | 0 |
_tLeukemia _gvol. 15 _gno. 6 _gp. 989-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.leu.2402137 _zAvailable from publisher's website |
| 999 |
_c11347311 _d11347311 |
||